MALVERN, Pa., April 9, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data published in a forthcoming issue of the Journal of Medicinal Chemistry of the American Chemical Society describes the discovery and unique chemical features of its lead Smac-mimetic birinapant, which is currently being tested in Phase 1 and Phase 2 clinical trials for hematological malignancies and solid tumors.
The publication entitled "Birinapant – A Smac-mimetic with Improved Tolerability for the Treatment of Solid Tumors and Hematological Malignancies" by Condon et al., will appear in the May edition of Journal of Medicinal Chemistry.
It is available on-line at:
The paper reports details of 10 compounds from TetraLogic's library of IAP-inhibitor compounds, and describes the differential properties of monovalent IAP-inhibitors versus bivalent Smac-mimetics. It further outlines the differences between the first-generation and second-generation bivalent molecules such as birinapant.
"We are delighted that this work is now published, as it describes, at the structural level, the characteristics of bivalent Smac-mimetics, and birinapant in particular and is the result of a long-standing and very fruitful collaboration between TetraLogic scientists and an outstanding group of collaborators." said C. Glenn Begley, Chief Scientific Officer of TetraLogic. "These data underpin our belief in birinapant's unique safety and efficacy profile."
TetraLogic is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases. Birinapant is currently being tested in Phase 1 and Phase 2 clinical trials for hematological malignancies and solid tumors. TetraLogic recently announced an agreement to acquire SHAPE, a small molecule that is entering Phase 2 trials for early-stage CTCL.
Forward Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements relate to future events or TetraLogic's pre-clinical and clinical development of birinapant, SHAPE and other clinical programs, future expectations, plans and prospects. Although TetraLogic believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. TetraLogic has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under the heading "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 19,2014. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
CONTACT: Company Contact: Pete A. Meyers Chief Financial Officer and Treasurer TetraLogic Pharmaceuticals Corporation (610) 889-9900, x103 email@example.com Investor Relations Contact: Ami Bavishi Burns McClellan, Inc. (212) 213-0006 firstname.lastname@example.org